Snowden Capital Advisors LLC Sells 60,885 Shares of Novo Nordisk A/S (NYSE:NVO)

Snowden Capital Advisors LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 49,433 shares of the company's stock after selling 60,885 shares during the quarter. Snowden Capital Advisors LLC's holdings in Novo Nordisk A/S were worth $4,252,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $404,910,000. Loomis Sayles & Co. L P boosted its stake in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its stake in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after purchasing an additional 1,602,549 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $2.59 during midday trading on Monday, reaching $66.96. 11,168,331 shares of the company traded hands, compared to its average volume of 6,596,989. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The firm has a market capitalization of $300.49 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The firm's fifty day moving average price is $67.31 and its two-hundred day moving average price is $84.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on NVO shares. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.